In the model of STZ-induced T1DM, an intraperitoneal injection of RvD1was able to increase the levels of the brain-derived neurotrophic factor with antidiabetic effects in pancreatic tissue, reduce the levels of TNF-α and IL-6 inflammatory factors in pancreatic tissue and plasma, and restore the expression of the downstream insulin signaling proteins Gsk-3β/FOXO1 and Bcl2/Pdx to promote β cell proliferation, thereby reducing the severity of STZ-induced T1DM (52). Here, FOXO1 is linked to type 1 diabetes mellitus.